ProCE Banner Activity

Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM

Slideset Download
Conference Coverage
The addition of ixazomib to lenalidomide/dexamethasone maintenance did not confer a PFS benefit in any subgroup of patients following the completion of ASCT, likely due to dose reductions/discontinuation associated with toxicity.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation